Shanghai InnoStar Bio-tech Co

Shanghai InnoStar Bio-tech Co Equity Turnover

The Equity Turnover of Shanghai InnoStar Bio-tech Co (688710.SS) as of Oct 20, 2026 is 0.35. In the previous year, Equity Turnover was 0.48 — a change of -26.84% (lower).

Equity Turnover

0.35

YoY

-26.84%

Last updated:

Equity Turnover of Shanghai InnoStar Bio-tech Co is 2025 0.35 . Equity Turnover of Shanghai InnoStar Bio-tech Co was 2024 0.48 . It decreases by -26.84% lower compared to the previous year.

The Shanghai InnoStar Bio-tech Co Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2021
0.83 CNY
Jan 1, 2022
0.61 CNY
Jan 1, 2023
0.64 CNY
Jan 1, 2024
0.48 CNY
Jan 1, 2025
0.35 CNY
The Shanghai InnoStar Bio-tech Co Equity Turnover history
YEAREquity TurnoverYoY
0.35-26.84%
0.48-25.63%
0.64+4.64%
0.61-26.52%
0.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai InnoStar Bio-tech Co Stock analysis

What does Shanghai InnoStar Bio-tech Co do? Shanghai InnoStar Bio-tech Co Ltd generates revenue through biopharmaceutical non-clinical research services, primarily targeting pharmaceutical companies and biotech firms. The company offers early drug development evaluation services that develop multiple early toxicity rapid prediction and screening models. Non-clinical research services include non-clinical safety evaluation, non-clinical pharmacokinetic research, and non-clinical pharmacodynamic research. Clinical testing and translational research provides analytical methods and data support for clinical pharmacokinetics, efficacy, and safety research of innovative drug projects. The firm's clients are pharmaceutical companies and biotech firms seeking to advance innovative drug projects through non-clinical and clinical research. These clients purchase the company's services to support early drug development, safety evaluation, and translational research needs. The company's focus on biopharmaceutical non-clinical research positions it to serve the growing demand for specialized research services in the life sciences sector. Shanghai InnoStar Bio-tech Co Ltd's service portfolio is structured around three core areas: early drug development evaluation, non-clinical research, and clinical testing and translational research. Each segment provides specialized services that support different stages of drug development, from initial toxicity screening to clinical research support. The company's revenue is derived from these specialized service offerings delivered to pharmaceutical and biotech clients. Shanghai InnoStar Bio-tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shanghai InnoStar Bio-tech Co stock

Equity Turnover of Shanghai InnoStar Bio-tech Co is 0.35 in 2025.

Equity Turnover of Shanghai InnoStar Bio-tech Co changed from 0.48 to 0.35, representing a -26.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Shanghai InnoStar Bio-tech Co since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Shanghai InnoStar Bio-tech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Shanghai InnoStar Bio-tech Co

All Key Metrics — Shanghai InnoStar Bio-tech Co